公开(公告)号：US11332521B2

公开(公告)日：2022-05-17

申请号：US16348058

申请日：2017-11-07

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol Kim ,  Jae Young Seong ,  Jong Ik Hwang ,  Eun Bee Cho ,  Junho Chung ,  Junyeong Jin ,  Tae Young Yune ,  Jee Youn Lee

IPC: C07K16/18 ,  C07K7/00 ,  A61K39/00 ,  G01N33/563

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20170121401A1

公开(公告)日：2017-05-04

申请号：US15404011

申请日：2017-01-11

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young SEONG ,  Jong Ik Hwang ,  Woong Sun ,  Eun Bee Cho ,  Won-Ki Kim

IPC: C07K16/24 ,  G01N33/577 ,  G01N33/68

CPC classification number: C07K16/24 ,  A61K38/1709 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4701 ,  C07K14/4702 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/577 ,  G01N33/6896 ,  G01N2333/47

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

公开(公告)号：US12202889B2

公开(公告)日：2025-01-21

申请号：US17723149

申请日：2022-04-18

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol Kim ,  Jae Young Seong ,  Jong Ik Hwang ,  Eun Bee Cho ,  Junho Chung ,  Junyeong Jin ,  Tae Young Yune ,  Jee Youn Lee

IPC: C07K16/18 ,  A61K39/00 ,  C07K7/00 ,  G01N33/563

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US11739141B2

公开(公告)日：2023-08-29

申请号：US16807902

申请日：2020-03-03

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young Seong ,  Jong Ik Hwang ,  Woong Sun ,  Eun Bee Cho ,  Won-Ki Kim

IPC: C07K16/24 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/577 ,  G01N33/68 ,  A61K39/00 ,  C07K14/47 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

CPC classification number: C07K16/24 ,  A61K38/1709 ,  A61K48/00 ,  C07K14/4701 ,  C07K14/4702 ,  C07K16/18 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/577 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/141 ,  C12Q2600/156 ,  G01N2333/47

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

公开(公告)号：US09579398B2

公开(公告)日：2017-02-28

申请号：US14378505

申请日：2013-02-15

Applicant: Neuracle Science Co., Ltd.

Inventor： Jae Young Seong ,  Jong Ik Hwang ,  Woong Sun ,  Eun Bee Cho ,  Won-ki Kim

IPC: A61K39/395 ,  A61P25/00 ,  A61K48/00 ,  A61K38/17 ,  C07K16/18 ,  C12N15/113 ,  C07K14/47 ,  C07K16/24 ,  C12Q1/68 ,  A61K39/00

CPC classification number: C07K16/24 ,  A61K38/1709 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4701 ,  C07K14/4702 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/577 ,  G01N33/6896 ,  G01N2333/47

Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

Abstract translation: 本发明涉及涉及调节胶质发生的FAM19A5的药物用途，更具体地说，涉及使用FAM19A5预防，诊断或治疗中枢神经系统损伤，退行性脑病或中枢神经系统疾病，FAM19A5为 在脊椎动物的神经干细胞中扩散并调节胶质细胞发生。